Navigation Links
Preliminary Data From Experimental Study Demonstrate Increased Mortality in Stroke Patients Treated With Epoetin Alfa
Date:9/17/2008

BRIDGEWATER, N.J., Sept. 17 /PRNewswire/ -- Ortho Biotech has become aware of preliminary data from an investigator-initiated experimental study of the effects of Epoetin alfa in patients with acute ischemic stroke. In this study, patients suffering acute ischemic stroke who were treated with Epoetin alfa within six hours of the onset of stroke symptoms died more frequently than patients receiving placebo. Ortho Biotech has reported this information to the U.S. Food and Drug Administration and to European regulatory authorities. Additional analyses are underway to better understand these preliminary results.

Epoetin alfa is marketed as EPREX(R) / ERYPO(R) outside the U.S. by Janssen-Cilag, as PROCRIT(R) in the U.S. by Ortho Biotech and as EPOGEN(R) in the U.S. by Amgen. None of these products are approved in any country for use in patients with acute ischemic stroke. Epoetin alfa is a member of the class of erythropoiesis-stimulating agents (ESAs). ESAs should be used strictly in accordance with their approved indications and dosing recommendations.

This investigator-initiated experimental study was designed and conducted by an investigator in Europe. Ortho Biotech provided study drug and funding, but the company had no role in designing or conducting the study. The investigator has informed the company that the results of this study will be submitted for publication promptly.


'/>"/>
SOURCE Ortho Biotech
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Trubion Announces Preliminary Analysis of Phase IIb Results With TRU-015 in Rheumatoid Arthritis
2. Genomic Health Announces Preliminary Results From a Study of Oncotype DX(TM) in Node-Positive Breast Cancer Patients
3. Preliminary Results of Randomized Pilot Study Show Comparable Efficacy for OrbusNeichs Genous(TM) Bio-engineered R Stent(TM) and Boston Scientifics Taxus(R) Stent in Patients at High Risk of Restenosis
4. Sunesis Pharmaceuticals Reports Preliminary SNS-595 Activity in Ovarian Cancer Clinical Trial at AACR-NCI-EORTC International Conference
5. Pharmion and MethylGene Report Preliminary MGCD0103 Clinical Data at the 2007 AACR-NCI-EORTC International Conference
6. Keryx Biopharmaceuticals, Inc. Announces Positive Preliminary Phase 2 Data on KRX-0401 in Patients with Chemo-Insensitive Rare Sarcoma
7. Vion Pharmaceuticals To Present Preliminary Data on its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) at the American Society of Hematology Meeting
8. Pixantrone Versus Doxorubicin in CHOP-R Therapy for First-line Treatment of Aggressive Non-Hodgkins Lymphoma Preliminary Results Presented at American Society of Hematology (ASH) Annual Meeting
9. Anthera Announces Preliminary Positive Results From Once-Daily A-002 Phase II Cardiovascular Trial
10. Morria Biopharmaceuticals Plc Announces Preliminary Safety and Tolerability Results From Its Phase I Clinical Study of MRX-4 in Allergic Rhinitis Patients
11. A Functional Immune System Can Be Derived From Embryonic Stem Cells, Preliminary Study Finds
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2016)... ALBANY, New York , May 23, 2016 /PRNewswire/ ... new market report titled, " Exocrine Pancreatic Insufficiency Market ... Forecast 2013 - 2023 ." According to the report, ... at a CAGR of 8.3% from 2015 to 2023 ... pancreatic insufficiency (EPI) is a condition characterized by the ...
(Date:5/23/2016)... May 23, 2016 Clarifying Vision ... and Monitoring, and Vision Care What can ... are going to grow at the fastest rates? This ... 2026, assessing data, trends, opportunities and prospects. ... graphs. Discover the most lucrative areas in the industry ...
(Date:5/23/2016)... JERUSALEM , May 23, 2016 ... DNA for detection of multiple diseases; ,Technology to be ... Yissum Research Development Company of the ... entered into a research agreement with Aurum Ventures MKI, the ... the development of a new diagnostic approach for early ...
Breaking Medicine Technology:
(Date:5/25/2016)... ... May 25, 2016 , ... The World Molecular Imaging ... Molecular Imaging.” The focus of ADDMI-IG will be geared towards how using molecular ... issues. Through ADDMI-IG WMIS will provide a platform for productive discussions about the ...
(Date:5/25/2016)... ... 2016 , ... DKT International, one of the largest private ... to release their 2015 global impact data. In 2015, DKT served over 30 ... and 3.8 million unsafe abortions across 21 countries worldwide. , “We are ...
(Date:5/25/2016)... (PRWEB) , ... May 25, 2016 , ... ... solutions to industries ranging from medical and pharmaceutical, to food and HVAC facilities. ... well as on-site training. , For medical applications, Afrimesure offers a variety ...
(Date:5/25/2016)... ... , ... Casa Velas, an adults-only boutique hotel in Puerto Vallarta, Mexico, introduces ... wellness suites . The two 1,350 sq. ft. suites which debuted in late ... insuite amenities, from a custom soap selection and in-suite exercise kit to a personal ...
(Date:5/25/2016)... CA (PRWEB) , ... May 25, 2016 , ... The ... of Nursing and Health Professions. She will lead a team of more than 100 ... Baker will begin her role as dean in late August. , Baker comes to ...
Breaking Medicine News(10 mins):